Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network.

Autor:	Avutu V; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY., Monga V; Division of Medical Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA., Mittal N; Division of Pediatric Hematology Oncology, Department of Pediatrics, Rush University Medical Center, Chicago, IL., Saha A; Division of Pediatric Hematology-Oncology, University of South Carolina School of Medicine, Greenville, SC., Andolina JR; Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY., Bell DE; Department of Pediatrics, Ascension St John Hospital, Detroit, MI., Fair DB; Division of Hematology/Oncology, Department of Pediatrics, University of Utah, Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Flerlage JE; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN., Frediani JN; Department of Pediatrics, University of California, Irvine, CA., Heath JL; Departments of Pediatrics and Biochemistry, University of Vermont, Burlington, VT., Kahn JM; Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY., Reichek JL; Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Super L; Department of Paediatrics, School of Medicine, Monash University, Melbourne, Australia., Terao MA; Division of Pediatric Adolescent and Young Adult Hematology and Oncology, Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC., Freyer DR; Departments of Pediatrics, Medicine, and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA., Roth ME; Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2022 Mar; Vol. 18 (3), pp. 224-231. Date of Electronic Publication: 2021 Dec 14.
DOI:	10.1200/OP.21.00554
Abstrakt:	Adolescents and young adults (AYAs; age 15-39 years) with cancer are under-represented in cancer clinical trials because of patient, provider, and institutional barriers. Health care technology is increasingly available to and highly used among AYAs and has the potential to improve cancer care delivery. The COVID-19 pandemic forced institutions to rapidly adopt novel approaches for enrollment and monitoring of patients on cancer clinical trials, many of which have the potential for improving AYA trial participation overall. This consensus statement from the Children's Oncology Group AYA Oncology Discipline Committee reviews opportunities to use technology to optimize AYA trial enrollment and study conduct, as well as considerations for widespread implementation of these practices. The use of remote patient eligibility screening, electronic informed consent, virtual tumor boards, remote study visits, and remote patient monitoring are recommended to increase AYA access to trials and decrease the burden of participation. Widespread adoption of these strategies will require new policies focusing on reimbursement for telehealth, license portability, facile communication between electronic health record systems and advanced safeguards to maintain patient privacy and security. Studies are needed to determine optimal approaches to further incorporate technology at every stage of the clinical trial process, from enrollment through study completion. Competing Interests: Varun MongaConsulting or Advisory Role: Forma TherapeuticsResearch Funding: Orbus Therapeutics (Inst), ImmunoCellular Therapeutics (Inst)¸ Newlink Genetics (Inst), Amgen (Inst), Prelude Therapeutics (Inst)Travel, Accommodations, Expenses: Deciphera (Inst), GlaxoSmithKline (Inst) Jamie E. FlerlageResearch Funding: Seattle Genetics (Inst) Michael A. TeraoOther Relationship: Sketchy MedicalUncompensated Relationships: theMednet Michael E. RothResearch Funding: Eisai, PfizerNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu